Toshi Yokota
@tyokota.bsky.social
Molecular Geneticist| RNA Therapeutics Innovator| FCAHS Canadian Academy Fellow| Distinguished Professor@UAlberta| Driving innovation in genetic medicine
Honoured that our FSHD antisense gapmer technology was recognized with a 2025 Innovation Award from
@ualberta.bsky.social
Technology Transfer Services, following its license to Facio BioTherapies and Children’s National Research Institute.
Grateful to our team and partners. #FSHD #RareDisease
@ualberta.bsky.social
Technology Transfer Services, following its license to Facio BioTherapies and Children’s National Research Institute.
Grateful to our team and partners. #FSHD #RareDisease
November 23, 2025 at 4:06 AM
Honoured that our FSHD antisense gapmer technology was recognized with a 2025 Innovation Award from
@ualberta.bsky.social
Technology Transfer Services, following its license to Facio BioTherapies and Children’s National Research Institute.
Grateful to our team and partners. #FSHD #RareDisease
@ualberta.bsky.social
Technology Transfer Services, following its license to Facio BioTherapies and Children’s National Research Institute.
Grateful to our team and partners. #FSHD #RareDisease
Congratulations to Harry from our lab for receiving the Oral Presentation Award at the 2025 WCHRI Research Day!
His talk, “Customized exon skipping therapy to treat a young boy with DMD” highlights the promise of precision antisense therapy for rare diseases.
@wchriuofa.bsky.social
His talk, “Customized exon skipping therapy to treat a young boy with DMD” highlights the promise of precision antisense therapy for rare diseases.
@wchriuofa.bsky.social
October 23, 2025 at 9:45 PM
Congratulations to Harry from our lab for receiving the Oral Presentation Award at the 2025 WCHRI Research Day!
His talk, “Customized exon skipping therapy to treat a young boy with DMD” highlights the promise of precision antisense therapy for rare diseases.
@wchriuofa.bsky.social
His talk, “Customized exon skipping therapy to treat a young boy with DMD” highlights the promise of precision antisense therapy for rare diseases.
@wchriuofa.bsky.social
🚀 Exciting news! Our team has been awarded a $1.3M CIHR grant to study Spinal-Bulbar Muscular Atrophy (SBMA) in Indigenous communities of the Prairie Provinces. Honored to collaborate with an incredible team of researchers & community leaders! @nmd4c.ca neuromuscularnetwork.ca/news/cihr-fu...
March 4, 2025 at 11:23 PM
🚀 Exciting news! Our team has been awarded a $1.3M CIHR grant to study Spinal-Bulbar Muscular Atrophy (SBMA) in Indigenous communities of the Prairie Provinces. Honored to collaborate with an incredible team of researchers & community leaders! @nmd4c.ca neuromuscularnetwork.ca/news/cihr-fu...